

Mustafa A-zgAeroglu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6423578/publications.pdf>

Version: 2024-02-01

242
papers

22,886
citations

76326

40
h-index

9103

144
g-index

249
all docs

249
docs citations

249
times ranked

18942
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2022, 25, 197-206.	5.3	72
2	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	7.0	18
3	Comparison of iodine-125 plaque brachytherapy and gamma knife stereotactic radiosurgery treatment outcomes for uveal melanoma patients. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2022, 260, 1337-1343.	1.9	4
4	Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). <i>Gastric Cancer</i> , 2022, 25, 586-597.	5.3	8
5	Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study. <i>European Journal of Cancer</i> , 2022, 162, 56-64.	2.8	14
6	An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction. <i>The Journal of Breast Health</i> , 2022, 18, 63-73.	1.0	0
7	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Nonâ€Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	1.6	445
8	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). <i>Lung Cancer</i> , 2022, 166, 107-113.	2.0	3
9	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. <i>Lung Cancer</i> , 2022, 166, 84-93.	2.0	7
10	Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.. <i>Journal of Clinical Oncology</i> , 2022, 40, 519-519.	1.6	0
11	Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. <i>Cancers</i> , 2022, 14, 1168.	3.7	0
12	Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro + chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.. <i>Journal of Clinical Oncology</i> , 2022, 40, 540-540.	1.6	1
13	First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 521-521.	1.6	0
14	The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.. <i>Journal of Clinical Oncology</i> , 2022, 40, 89-89.	1.6	4
15	CLOZZ-074: Patient-Reported Outcomes (PROs) in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) With Programmed Cell Death-Ligand 1 (PD-L1) â€¥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EMPOWER-Lung 1 Brain Metastases Subpopulation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 0122-074.	4.9	0
16	Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. <i>European Journal of Cancer</i> , 2022, 170, 73-84.	2.8	10
17	Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5019-5019.	1.6	2
18	Adverse events self-reported by patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with durvalumab (D) plus platinum-etoposide (EP) or EP in the CASPIAN study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8571-8571.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN.. Journal of Clinical Oncology, 2022, 40, 5066-5066.	1.6	4
20	Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer. Tumori, 2021, 107, 304-310.	1.1	3
21	PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. Future Oncology, 2021, 17, 137-149.	2.4	5
22	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. Journal of Clinical Oncology, 2021, 39, 966-977.	1.6	122
23	Durvalumab, with or without tremelimumab, plus platinum+etoposide versus platinum+etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 51-65.	10.7	356
24	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer, 2021, 151, 30-38.	2.0	30
25	The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer. Medical Oncology, 2021, 38, 11.	2.5	0
26	Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.. Journal of Clinical Oncology, 2021, 39, 435-435.	1.6	1
27	Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet, The, 2021, 397, 592-604.	13.7	441
28	1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.. Journal of Clinical Oncology, 2021, 39, 450-450.	1.6	10
29	Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2021, 39, 439-439.	1.6	2
30	Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2021, 39, 11-11.	1.6	6
31	Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.. Journal of Clinical Oncology, 2021, 39, 321-321.	1.6	1
32	Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2021, 39, 448-448.	1.6	2
33	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. Oncologist, 2021, 26, e769-e779.	3.7	48
34	A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 531-540.	2.6	15
35	Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial. Lung Cancer, 2021, 154, 92-98.	2.0	3
36	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncology, 2021, 17, 1165-1184.	2.4	2

#	ARTICLE	IF	CITATIONS
37	Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2021, 39, 5068-5068.	1.6	2
38	Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 â%¥ 50%: Results from EMPOWER-Lung 1 study.. Journal of Clinical Oncology, 2021, 39, 9078-9078.	1.6	3
39	Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.. Journal of Clinical Oncology, 2021, 39, 8511-8511.	1.6	74
40	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLCâ€”an Update From the PACIFIC Trial. Journal of Thoracic Oncology, 2021, 16, 860-867.	1.1	323
41	Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) â%¥ 50%: EMPOWER-Lung 1 subgroup analysis.. Journal of Clinical Oncology, 2021, 39, 9085-9085.	1.6	6
42	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instabilityâ€”High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncology, 2021, 7, 895.	7.1	184
43	Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Nonâ€”Smallâ€”Cell Lung Cancer (PACIFIC). Clinical Lung Cancer, 2021, 22, 549-561.	2.6	25
44	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 931-945.	10.7	337
45	Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. Journal of Clinical Oncology, 2021, 39, 2294-2303.	1.6	218
46	Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Nonâ€”small-cell Lung Cancer: LAURA Trial in Progress. Clinical Lung Cancer, 2021, 22, 371-375.	2.6	44
47	Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial. Journal of Thoracic Oncology, 2021, 16, 1369-1378.	1.1	31
48	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. Gastric Cancer, 2021, 24, 1330-1340.	5.3	7
49	Reply by Authors. Journal of Urology, 2021, 206, 923-923.	0.4	0
50	Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. Journal of Urology, 2021, 206, 914-923.	0.4	9
51	Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Future Oncology, 2021, 17, 4861-4869.	2.4	2
52	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCâ€”Update from PACIFIC. Journal of Thoracic Oncology, 2020, 15, 288-293.	1.1	328
53	Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. European Urology, 2020, 77, 494-500.	1.9	54
54	Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis. European Urology Open Science, 2020, 19, e863-e864.	0.4	2

#	ARTICLE	IF	CITATIONS
55	LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) $\geq 50\%$. Annals of Oncology, 2020, 31, S1182-S1183.	1.2	18
56	LBA86 Durvalumab (D) \pm tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Annals of Oncology, 2020, 31, S1212-S1213.	1.2	23
57	6100 Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Annals of Oncology, 2020, 31, S508.	1.2	7
58	LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial. Annals of Oncology, 2020, 31, S1178-S1179.	1.2	24
59	O81...IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1-selected NSCLC. , 2020, , .		6
60	Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study. Lung Cancer, 2020, 149, 46-52.	2.0	28
61	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2020, 383, 2345-2357.	27.0	440
62	1459P Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials. Annals of Oncology, 2020, 31, S915.	1.2	1
63	624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound. Annals of Oncology, 2020, 31, S515-S516.	1.2	0
64	651P Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study. Annals of Oncology, 2020, 31, S530-S531.	1.2	0
65	374TiP LAURA: Osimertinib maintenance following definitive chemoradiation therapy (CRT) in patients (pts) with unresectable stage III epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC). Annals of Oncology, 2020, 31, S1385.	1.2	2
66	378MO EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) $\geq 50\%$. Annals of Oncology, 2020, 31, S1388.	1.2	5
67	379MO Durvalumab (D) \pm tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN. Annals of Oncology, 2020, 31, S1388-S1389.	1.2	2
68	LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Annals of Oncology, 2020, 31, S1155.	1.2	49
69	Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2020, 395, 1547-1557.	13.7	546
70	Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Annals of Oncology, 2020, 31, 798-806.	1.2	131
71	O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology, 2020, 31, 236.	1.2	6
72	Atezolizumab for First-Line Treatment of PD-L1-selected Patients with NSCLC. New England Journal of Medicine, 2020, 383, 1328-1339.	27.0	959

#	ARTICLE	IF	CITATIONS
73	Pembrolizumab versus paclitaxel for previously treated patients with PD-L1â€“positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. Journal of Clinical Oncology, 2020, 38, 4503-4503.	1.6	31
74	The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.. Journal of Clinical Oncology, 2020, 38, 4512-4512.	1.6	26
75	The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.. Journal of Clinical Oncology, 2020, 38, 4537-4537.	1.6	38
76	Durvalumab Â± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.. Journal of Clinical Oncology, 2020, 38, 9002-9002.	1.6	36
77	Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).. Journal of Clinical Oncology, 2020, 38, 9048-9048.	1.6	1
78	First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.. Journal of Clinical Oncology, 2020, 38, 9068-9068.	1.6	10
79	Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2â€“ advanced gastric or gastroesophageal junction cancer (G/GEJC).. Journal of Clinical Oncology, 2020, 38, 278-278.	1.6	39
80	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.. Journal of Clinical Oncology, 2020, 38, 430-430.	1.6	20
81	PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. Journal of Clinical Oncology, 2020, 38, 134-134.	1.6	6
82	Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane).. Journal of Clinical Oncology, 2020, 38, 82-82.	1.6	12
83	Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease.. Journal of Clinical Oncology, 2020, 38, 87-87.	1.6	5
84	PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2020, 38, TPS589-TPS589.	1.6	0
85	Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.. Journal of Clinical Oncology, 2020, 38, e13646-e13646.	1.6	0
86	Abstract CT213: Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC). , 2020, , .		0
87	CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab Â± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab Â± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC). , 2020, 74. , .		0
88	PD10-11â€“APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES. Journal of Urology, 2020, 203, .	0.4	0
89	Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061). Annals of Oncology, 2019, 30, v304.	1.2	2
90	Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC). Annals of Oncology, 2019, 30, v330-v331.	1.2	1

#	ARTICLE	IF	CITATIONS
91	Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC). <i>Annals of Oncology</i> , 2019, 30, v592-v593.	1.2	11
92	Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2019, 30, v611-v612.	1.2	3
93	PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN. <i>Annals of Oncology</i> , 2019, 30, v928-v929.	1.2	32
94	A challenging task â€“ Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience. <i>Annals of Oncology</i> , 2019, 30, v813-v814.	1.2	3
95	IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1â€“selected NSCLC. <i>Annals of Oncology</i> , 2019, 30, v915.	1.2	97
96	Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1670-1680.	10.7	125
97	Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1518-1530.	10.7	69
98	PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, S7-S8.	1.1	17
99	Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. <i>Annals of Oncology</i> , 2019, 30, v328-v329.	1.2	32
100	Durvalumab plus platinumâ€“etoposide versus platinumâ€“etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1929-1939.	18.7	1,274
101	Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 13-24.	27.0	904
102	Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 686-700.	10.7	496
103	KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. <i>Future Oncology</i> , 2019, 15, 1057-1066.	2.4	132
104	IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). <i>Annals of Oncology</i> , 2019, 30, v888-v889.	1.2	28
105	Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience. <i>Annals of Oncology</i> , 2019, 30, xi19.	1.2	0
106	Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia. <i>Annals of Oncology</i> , 2019, 30, ix197-ix198.	1.2	1
107	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. <i>Clinical Lung Cancer</i> , 2019, 20, e407-e412.	2.6	12
108	Three-year overall survival update from the PACIFIC trial. <i>Annals of Oncology</i> , 2019, 30, ix108-ix109.	1.2	1

#	ARTICLE	IF	CITATIONS
109	Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥ 65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.. Journal of Clinical Oncology, 2019, 37, 4037-4037.	1.6	5
110	First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2019, 37, 5006-5006.	1.6	4
111	Three-year overall survival update from the PACIFIC trial.. Journal of Clinical Oncology, 2019, 37, 8526-8526.	1.6	29
112	First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.. Journal of Clinical Oncology, 2019, 37, 9054-9054.	1.6	3
113	Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2019, 37, 141-141.	1.6	7
114	Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study. Annals of Oncology, 2019, 30, ix68.	1.2	0
115	Durvalumab in Stage III Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 868-870.	27.0	33
116	An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting. European Journal of Cancer, 2018, 92, S102-S103.	2.8	2
117	Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents. Clinical Genitourinary Cancer, 2018, 16, e777-e784.	1.9	20
118	Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. JAMA Oncology, 2018, 4, 977.	7.1	48
119	Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry. Journal of Global Oncology, 2018, 4, 1-12.	0.5	11
120	Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Annals of Oncology, 2018, 29, viii488.	1.2	25
121	Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Annals of Oncology, 2018, 29, viii413.	1.2	12
122	P1.16-04 Outcomes of Patients < 70 or ≥ 70 Years of Age in PACIFIC. Journal of Thoracic Oncology, 2018, 13, S628-S629.	1.1	2
123	P1.16-06 Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%. Journal of Thoracic Oncology, 2018, 13, S629-S630.	1.1	0
124	PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1607-1608.	0.8	2
125	PL02.01 Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC. Journal of Thoracic Oncology, 2018, 13, S184.	1.1	6
126	OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial. Journal of Thoracic Oncology, 2018, 13, S331-S332.	1.1	2

#	ARTICLE	IF	CITATIONS
127	P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study. Journal of Thoracic Oncology, 2018, 13, S629.	1.1	1
128	MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT. Journal of Thoracic Oncology, 2018, 13, S370-S371.	1.1	35
129	Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncology, The, 2018, 19, 1468-1479.	10.7	370
130	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 2018, 379, 2342-2350.	27.0	2,150
131	2330 Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes. Journal of Thoracic Oncology, 2018, 13, S71.	1.1	0
132	Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptorâ€“Positive, HER2-Negative Advanced Breast Cancer. JAMA Oncology, 2018, 4, 1367.	7.1	67
133	KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer. Annals of Oncology, 2018, 29, v123.	1.2	29
134	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	13.7	984
135	Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.. Journal of Clinical Oncology, 2018, 36, 1005-1005.	1.6	2
136	Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.. Journal of Clinical Oncology, 2018, 36, 4062-4062.	1.6	10
137	Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR) Tj ETQq1 1 0.7&4314 rgBT /Overlo	1.6	1
138	Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial.. Journal of Clinical Oncology, 2018, 36, 5028-5028.	1.6	1
139	Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.. Journal of Clinical Oncology, 2018, 36, TPS9117-TPS9117.	1.6	1
140	JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).. Journal of Clinical Oncology, 2018, 36, TPS195-TPS195.	1.6	12
141	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine, 2017, 377, 352-360.	27.0	1,588
142	Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenterâ€“Study. Clinical Genitourinary Cancer, 2017, 15, e469-e476.	1.9	11
143	Durvalumab after Chemoradiotherapy in Stage III Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 1919-1929.	27.0	3,261
144	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1688-1700.	10.7	451

#	ARTICLE	IF	CITATIONS
145	PL 02.02 Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1604.	1.1	4
146	PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC. <i>Annals of Oncology</i> , 2017, 28, v634.	1.2	4
147	Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2~) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1010-1010.	1.6	6
148	LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA3-LBA3.	1.6	2
149	Abstract P2-11-08: Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial. , 2017, , .		0
150	TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC). <i>Annals of Oncology</i> , 2016, 27, vi265.	1.2	6
151	Cost of Treatment of HR+/HER2- Post Menopausal Advanced/Metastatic Breast Cancer Patients in Turkey. <i>Value in Health</i> , 2016, 19, A146.	0.3	1
152	Abstract P4-13-12: Everolimus plus trastuzumab and vinorelbine for trastuzumab-resistant, taxane-pretreated, HER2+ advanced breast cancer: Overall survival results from BOLERO-3. , 2016, , .		2
153	Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9105-TPS9105.	1.6	6
154	2549 Treatment patterns in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CT): PROXIMA 1-year analysis. <i>European Journal of Cancer</i> , 2015, 51, S492-S493.	2.8	0
155	2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel. <i>European Journal of Cancer</i> , 2015, 51, S488.	2.8	0
156	2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting. <i>European Journal of Cancer</i> , 2015, 51, S489.	2.8	2
157	2612 Prognostic value of baseline Neutrophil to Lymphocyte Ratio (NLR) in metastatic Urothelial Carcinomas (mUC) patients (pts) treated with first-line chemotherapy (CT): A large retrospective multicenter study. <i>European Journal of Cancer</i> , 2015, 51, S515-S516.	2.8	0
158	Clinical experience with Vemurafenib in pretreated melanoma (MEL): The results of open label multi center study from Turkey.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20085-e20085.	1.6	0
159	Receptor Expression Discrepancy between Primary and Metastatic Breast Cancer Lesions. <i>Oncology Research and Treatment</i> , 2014, 37, 622-626.	1.2	9
160	Quality-of-Life in Turkish Cancer Patients: The Impact of Sociodemographic Characteristics, Medical History, and Management.. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2014, 24, 23-29.	0.1	2
161	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 580-591.	10.7	434
162	Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. <i>British Journal of Cancer</i> , 2014, 110, 1968-1976.	6.4	11

#	ARTICLE	IF	CITATIONS
163	Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2014, 50, 1602-1609.	2.8	50
164	Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 282-282.	1.6	16
165	Re: Germline BRCA Mutations are Associated with Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 2093-2094.	0.4	3
166	Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 253-271.	4.4	195
167	Primary Osteosarcoma of the Heart: Experience of an Unusual Case. <i>Case Reports in Oncology</i> , 2013, 6, 224-228.	0.7	7
168	Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. <i>Annals of Oncology</i> , 2013, 24, 2402-2408.	1.2	126
169	Patterns of Complementary and Alternative Medicine Use among Turkish Cancer Patients. <i>Journal of Palliative Medicine</i> , 2013, 16, 383-390.	1.1	27
170	Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience. <i>World Journal of Gastroenterology</i> , 2013, 19, 2154.	3.3	11
171	A Case of Complete Response to Letrozol Treatment in a Postmenopausal Woman With Breast Cancer Who has Progressed After Multiple Lines of Chemotherapy. <i>World Journal of Oncology</i> , 2013, 4, 58-60.	1.5	1
172	Clinicopathological Features and Localization of Gastric Cancers and their Effects on Survival in Turkey. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 553-556.	1.2	8
173	Abstract P4-12-18: BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine. , 2013, , .		0
174	Breast carcinoma metastasis to endometrial polyp (Case report and literature review). <i>Cumhuriyet Medical Journal</i> , 2013, 35, 589-592.	0.1	0
175	Primary Gastric Lymphoma: Conservative Treatment Modality Is Not Inferior to Surgery for Early-Stage Disease. <i>ISRN Oncology</i> , 2012, 2012, 1-6.	2.1	8
176	Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain. <i>Onkologie</i> , 2012, 35, 254-258.	0.8	8
177	Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3640-3647.	1.6	166
178	A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. <i>Journal of Clinical Oncology</i> , 2012, 30, 172-172.	1.6	1
179	Prognostic factors for survival in the phase III TROPIC trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 102-102.	1.6	1
180	A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15112-e15112.	1.6	0

#	ARTICLE	IF	CITATIONS
181	7044 POSTER Cabazitaxel Plus Prednisone for Patients With Metastatic Castration-resistant Prostate Cancer Previously Treated With a Docetaxel-containing Regimen " Interim Analysis Results From an Ongoing Compassionate-use Programme. <i>European Journal of Cancer</i> , 2011, 47, S498.	2.8	0
182	6037 POSTER Preoperative Chemoradiotherapy Improves Local Recurrence Free Survival in Locally Advanced Rectal Cancer. <i>European Journal of Cancer</i> , 2011, 47, S402.	2.8	0
183	5046 POSTER Tumour Characteristics Determining Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. <i>European Journal of Cancer</i> , 2011, 47, S344.	2.8	0
184	6020 POSTER KRas and Braf: Is a Predictor in Metastatic Colorectal Cancer Patients for Bevacizumab?. <i>European Journal of Cancer</i> , 2011, 47, S397.	2.8	0
185	Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi's Sarcoma of the Lymph Node: A Diagnostic Challenge and a Rare Coincidence. <i>Case Reports in Oncology</i> , 2011, 4, 439-444.	0.7	3
186	Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 4525-4525.	1.6	12
187	A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 4526-4526.	1.6	13
188	Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel.. <i>Journal of Clinical Oncology</i> , 2011, 29, e15131-e15131.	1.6	1
189	Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study.. <i>Journal of Clinical Oncology</i> , 2011, 29, 144-144.	1.6	8
190	Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: report of first case. <i>Archives of Gynecology and Obstetrics</i> , 2010, 282, 587-590.	1.7	5
191	Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center. <i>Medical Oncology</i> , 2010, 27, 1050-1056.	2.5	13
192	Surgery for Isolated Liver Metastasis of Ovarian Cancer. <i>Asian Journal of Surgery</i> , 2010, 33, 83-88.	0.4	13
193	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. <i>Lancet, The</i> , 2010, 376, 1147-1154.	13.7	2,857
194	Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC).. <i>Journal of Clinical Oncology</i> , 2010, 28, 4508-4508.	1.6	49
195	Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.. <i>Journal of Clinical Oncology</i> , 2010, 28, e19507-e19507.	1.6	1
196	How does 18f-FDG PET-CT scan affect clinical judgment and change treatment decisions in patients with epithelial ovarian cancer?. <i>Journal of Clinical Oncology</i> , 2010, 28, 5053-5053.	1.6	0
197	Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Case-Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 454-457.	1.7	5
198	Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study. <i>Medical Oncology</i> , 2008, 25, 257-263.	2.5	6

#	ARTICLE	IF	CITATIONS
199	Determining predominating histologic component in malignant mixed mllerian tumors: is it worth it?. International Journal of Gynecological Cancer, 2008, 18, 809-812.	2.5	17
200	Paraneoplastic pemphigus associated with fludarabine use. Medical Oncology, 2007, 24, 115-118.	2.5	17
201	Thymoma with chronic diarrhea. Medical Oncology, 2007, 24, 119-123.	2.5	5
202	C-reactive protein as an acute phase protein in cancer patients. Medical Oncology, 2007, 24, 338-344.	2.5	15
203	A caseâ€“control study of non-alcoholic fatty liver disease in breast cancer. Medical Oncology, 2007, 24, 367-371.	2.5	36
204	Devastating effects of chemotherapy: deafness and acute renal failure in a patient with epithelial ovarian cancer. International Journal of Gynecological Cancer, 2006, 16, 394-396.	2.5	8
205	Adult Paratesticular Myxofibrosarcoma: Report of a Rare Entity and Review of the Literature. International Urology and Nephrology, 2006, 38, 5-7.	1.4	16
206	Small Cell Carcinoma of the Bladder: A Case Report and Review of the Literature. International Urology and Nephrology, 2006, 38, 15-19.	1.4	7
207	Skeletal muscle: An unusual site of distant metastasis in gastric carcinoma. Radiation Medicine, 2006, 24, 150-153.	0.8	28
208	Megestrol acetate induced hypoadrenalism with cushingoid phenotype in endometrial cancer. Gynecologic Oncology, 2006, 101, 183.	1.4	3
209	Idiopathic thrombocytopenia associated with dysgerminoma in a patient with androgen insensitivity syndrome. Gynecologic Oncology, 2005, 99, 248.	1.4	2
210	Toxicity and Survival Results of a Phase II Study Investigating the Role of Postoperative Chemo-radioimmunotherapy for Gastric Adenocarcinoma. Strahlentherapie Und Onkologie, 2005, 181, 652-659.	2.0	8
211	Does the incidence of anal canal cancers differ in Moslem societies?. International Journal of Colorectal Disease, 2005, 20, 76-76.	2.2	1
212	Role of the antiangiogenetic drug paclitaxel on healing of intestinal anastomosis: an experimental study. Techniques in Coloproctology, 2005, 9, 201-205.	1.8	3
213	Secretory Carcinoma of the Breast. Oncology, 2005, 68, 263-268.	1.9	30
214	Delayed onset bleomycin-induced pneumonitis. Urology, 2005, 66, 195.	1.0	33
215	Reactivation of Hepatitis B Virus Infection with Cytotoxic Therapy in Non-Hodgkin's Lymphoma. Medical Oncology, 2004, 21, 67-72.	2.5	39
216	Should Mammographic Screening Be Done in Primary Ovarian Cancer?: A Case Control Study in Turkish Women. Medical Oncology, 2004, 21, 139-144.	2.5	0

#	ARTICLE	IF	CITATIONS
217	Rituximab-Induced Tumor Progression: Does It Really Happen?. <i>Medical Oncology</i> , 2004, 21, 205-206.	2.5	10
218	Acute Leukemia in a Patient with Ocular Melanoma: Is It Induced by Intraocular Brachytherapy or Only a Bad Fate?. <i>Medical Oncology</i> , 2004, 21, 373-374.	2.5	0
219	Is the incidence of anal canal cancers different in Moslem societies?. <i>Journal of Clinical Oncology</i> , 2004, 22, 4233-4233.	1.6	0
220	Gastric cancer in Turkey: A single center experience of 683 cases. <i>Journal of Clinical Oncology</i> , 2004, 22, 4254-4254.	1.6	0
221	Intrathoracic Extravasation of Antineoplastic Agents. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 121-123.	1.3	44
222	Primary granulocytic sarcoma of the urinary bladder: case report and review of the literature. <i>Urology</i> , 2002, 60, 345.	1.0	29
223	Simultaneous Presentation of Hepatocellular Carcinoma in Identical Twin Brothers. <i>Medical Oncology</i> , 2002, 19, 113-116.	2.5	13
224	Flutamide-Induced Acute Renal Failure in a Patient with Metastatic Prostate Cancer. <i>Medical Oncology</i> , 2002, 19, 117-120.	2.5	11
225	Metastatic cardiac myxoma. <i>Annals of Thoracic Surgery</i> , 2001, 72, 623-625.	1.3	18
226	Serum erythropoietin level in anemic cancer patients. <i>Medical Oncology</i> , 2000, 17, 29-34.	2.5	32
227	Unusual Manifestations of B-Cell Disorders. <i>Journal of Clinical Oncology</i> , 1999, 17, 1083-1083.	1.6	9
228	Serum Cardiolipin Antibodies in Cancer Patients with Thromboembolic Events. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 1999, 5, 181-184.	1.7	17
229	Magnetic resonance imaging of bone marrow versus bone marrow biopsy in malignant lymphoma. <i>Pathology and Oncology Research</i> , 1999, 5, 123-128.	1.9	6
230	Serum erythropoietin level in anemic cancer patients. <i>European Journal of Cancer</i> , 1999, 35, S105.	2.8	0
231	Chemoimmunotherapy protocol for advanced gastric cancer. <i>European Journal of Cancer</i> , 1999, 35, S152.	2.8	0
232	Role of mammographic screening in ovarian cancer. <i>European Journal of Cancer</i> , 1999, 35, S245.	2.8	0
233	Anaphylaxis From Intraperitoneal Infusion of Cisplatin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 172-173.	1.3	7
234	Microangiopathic Hemolytic Anemia As an Early Predictor of Recurrence in Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 214.	1.3	5

#	ARTICLE	IF	CITATIONS
235	Bilateral Inflammatory Breast Metastases of Epithelial Ovarian Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 408-410.	1.3	32
236	Paraneoplastic Hyperpigmentation Secondary to Lung Cancer Resolving After Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 533.	1.3	1
237	Usefulness of the Epithelial Tumor Marker CA-125 in Non-Hodgkinâ€™s Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 615.	1.3	21
238	Primary Splenic Tuberculosis in a Patient With Nasal Angiocentric Lymphoma. Journal of Clinical Gastroenterology, 1999, 29, 96-98.	2.2	9
239	Anorectal Melanoma Metastatic to the Breast. Journal of Clinical Gastroenterology, 1999, 29, 197-199.	2.2	12
240	A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-â€œfluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Cancer, 1998, 83, 2475-2480.	4.1	11
241	Magnetic resonance imaging of bone marrow versus biopsy in malignant lymphoma. European Journal of Cancer, 1997, 33, S270.	2.8	0
242	Generalized telangiectasia as the major manifestation of angiotropic (intravascular) lymphoma. British Journal of Dermatology, 1997, 137, 422-425.	1.5	38